Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema
Abstract
To provide 2-year results comparing anti-vascular endothelial growth factor (VEGF) agents for center-involved diabetic macular edema (DME) using a standardized follow-up and retreatment regimen.Randomized clinical trial.Six hundred sixty participants with visual acuity (VA) impairment from DME.Randomization to 2.0-mg aflibercept, 1.25-mg repackaged (compounded) bevacizumab, or 0.3-mg ranibizumab intravitreous injections performed up to monthly...
Paper Details
Title
Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema
Published Date
Jun 1, 2016
Journal
Volume
123
Issue
6
Pages
1351 - 1359
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History